Share Name Share Symbol Market Type Share ISIN Share Description
Alligator Bioscience Ab LSE:0RK9 London Ordinary Share SE0000767188 ALLIGATOR BIOSCIENCE ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +SEK0.00 +0.00% SEK23.00 SEK0.00 SEK0.00 - - - 0 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Alligator Bioscience AB (publ) Interim Report January-March 2019

17/04/2019 7:25am

PR Newswire (US)

Alligator Bioscience Ab (LSE:0RK9)
Historical Stock Chart

6 Months : From Jan 2019 to Jul 2019

Click Here for more Alligator Bioscience Ab Charts.

STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March

  • First patient dosed in Phase I clinical study of ATOR-1015.
  • New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017.
  • Alligator Bioscience launched RUBY™, a novel concept in bispecific antibody formats.

Events after the end of the period

  • Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.
  • New preclinical data for ATOR-1144 demonstrates potential for activation of both the innate and the adaptive immune system as well as direct anti-tumor effects.

Financial information

January-March 2019

  • Net sales, SEK 0.0 million (0.8)
  • Total operating costs SEK -46.7 million (-45.0)
  • Operating result, SEK -46.2 million (-44.0)
  • Earnings per share before and after dilution, SEK -0.62 (-0.59)
  • Cash flow for the period, SEK -34.3 million (0.8)
  • Cash and cash equivalents, including securities, SEK 402.9 million (436.4)
  • "This is a very exciting year for Alligator. We currently have two projects – ADC-1013 and ATOR-1015 – in clinical development. These projects will soon be joined by ATOR-1017," CEO Per Norlén comments.

    Read the complete report in the pdf below.

    The information was submitted for publication at 8:00 a.m. CEST on April 17, 2019.

    For further information, please contact:

    Per Norlén

    Per-Olof Schrewelius

    Cecilia Hofvander
    Director IR & Communications

    Alligator Bioscience AB (publ) 556597-8201
    Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
    Phone +46-46-540-82-00

    About Alligator Bioscience

    Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit

    ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

    This information was brought to you by Cision,c2789720

    The following files are available for download:

    Alligator Bioscience AB (publ) Interim report January-March 2019

    Cision View original content:

    SOURCE Alligator Bioscience

    Copyright 2019 PR Newswire

    1 Year Alligator Bioscience Ab Chart

    1 Year Alligator Bioscience Ab Chart

    1 Month Alligator Bioscience Ab Chart

    1 Month Alligator Bioscience Ab Chart
    Your Recent History
    Alligator ..
    Register now to watch these stocks streaming on the ADVFN Monitor.

    Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    P: V:gb D:20190723 05:06:47